A Multicenter, Randomized, Parallel-group, Double-blind, Two-arm, Phase III Study to Evaluate the Safety and Efficacy of Anifrolumab Compared with Placebo in Male and Female Participants 18 to 70 Years of Age Inclusive with Systemic Sclerosis

Status: Recruiting

Eligibility Criteria

Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- 18 to 70 years old - diagnosis of systemic sclerosis within 6 years from first non-Raynaud's symptoms - skin at injections sites is without symptoms - see link to clinicaltrials.gov for complete inclusion and exclusion criteria

Exclusion Criteria:

- severe heart or lung disease - history of any other inflammatory diseases - history of hematopoietic stem cell transplantation or solid organ or limb transplantation - current or a history of cancer within past 5 years - active current or history of reoccurring infections

Conditions & Interventions

Conditions:
Arthritis & Rheumatic Diseases
Keywords:
Clinics and Surgery Center (CSC), systemic sclerosis, Scleroderma

More Information

Description: We are doing this study to learn more about anifrolumab (SAPHNELOTM) in patients with systemic sclerosis and to better understand the studied disease and associated health problems. Systemic sclerosis (scleroderma) affects the skin as well as other organs, such as blood vessels, muscles and joints, digestive tract, kidneys, lungs and heart.
Study Contact: Eera Kale - kale0092@umn.edu
Principal Investigator: Jerry Molitor
Phase: PHASE3
IRB Number: STUDY00019243